Third Harmonic Bio Inc

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Third Harmonic Bio, Inc. (THRD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences:

Third Harmonic Bio to Participate in Upcoming Investor Conferences in November

THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million  as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. “As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress in preparing to move efficiently into a Phase 2 clinical trial in chronic spontaneous urticaria,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio.

Third Harmonic Bio Announces Third Quarter 2024 Financial Results

SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences:

Third Harmonic Bio to Participate in Upcoming Investor Conferences in September

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences:

Third Harmonic Bio to Participate in Upcoming Investor Conferences

THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million  as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the second quarter June 30, 2024, along with business updates. “We are making excellent progress in our Phase 1 SAD/MAD clinical trial of THB335 and now expect to report clinical results during the first quarter of 2025,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio.

Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET.

Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference

U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway,  with results expected during 1H'25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D.

Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. “Our team's execution continues to be outstanding, with the filing of our U.S. IND for THB335 ahead of our internal timelines for submission,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio.

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET.

Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference

NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders.  The investigation seeks to determine whether Third Harmonic Bio's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)

Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy

Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update

Does Third Harmonic Bio, Inc. (THRD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice

On track to file a U.S. Investigational New Drug (IND) application for THB335 and  initiate clinical studies in 1H'24

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023. In his new role, Dr. Ray will continue support the company's Investigational New Drug (IND) application for THB335, which is expected to be filed during the first half of 2024. Additionally, the company announced that Robert Ho, Chief Financial Officer, will depart the organization on November 10, 2023. The company has initiated executive searches for their successors.

Third Harmonic Bio Announces Leadership Changes

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET.

Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference

Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution, and physicochemical profile

Third Harmonic Bio Announces Second Quarter 2023 Financial Results

NEW YORK , Aug. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Third Harmonic Bio, Inc. (NASDAQ: THRD). If you are a shareholder of Third Harmonic Bio, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/third-harmonic-bio-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Third Harmonic Bio, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile

Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases

Third Harmonic Bio Announces First Quarter 2023 Financial Results

Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results

Amgen

AstraZeneca

1Life Healthcare

Pfizer

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)

AbbVie

Fate Therapeutics

Bio-Techne

5 Cheapest Health Care Stocks You Should Think About

Cutera

Baxter

Tricida Inc

Vera Therapeutics

5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)

News for Third Harmonic Bio Inc Stock (THRD)